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Human and Mouse Mast Cells Express and Secrete
the GPI-Anchored Isoform of CD160
Nicolas Ortonne1,5, Caroline Ram-Wolff1,5, Je´roˆme Giustiniani2, Anne Marie-Cardine2, Martine Bagot2,3,
Salaheddine Mecheri4 and Armand Bensussan2
CD160 is expressed by human and mouse natural killer (NK) cells and other cytotoxic lymphocyte
subpopulations. CD160 is mostly expressed as a trimeric 83 kDa glycosylphosphatidylinositol (GPI)-anchored
activating NK receptor, cleaved upon IL-15 stimulation in a secreted trimeric soluble form (sCD160) that binds to
major histocompatibility complex (MHC) class I molecules, while a transmembrane isoform appears. sCD160
exhibits immunoregulatory function as it inhibits CD8þ T-lymphocyte cytotoxic activity. We show that human
mast cells (MCs) express CD160. In human and mouse skin, resident MCs expressed CD160, whereas in C57BL/
6-KitW-sh/W-sh mice, CD160þ cells were only identified at the site of reconstitution with syngeneic cultured MCs.
In the human mast cell line, HMC-1, we only identified the transcripts of the GPI-anchored CD160 isoform.
Furthermore, CD160 was identified in HMC-1 and mouse MC supernatants, suggesting that MCs release
sCD160. Supporting this hypothesis, HMC-1 express the GPI-specific phospholipase D variant 2 involved in the
NK lymphocyte membrane cleavage of CD160, and morphological studies highlighted a relative loss of CD160
expression in inflammatory skin sites, where MC degranulation is expected to occur. We also demonstrated an
inhibition of T-cell cytotoxicity by HMC-1 supernatant that was partially reversed by anti-CD160 mAb. In
conclusion, sCD160, produced by MCs, may have a role in T-cell–MC interactions in vivo.
Journal of Investigative Dermatology (2011) 131, 916–924; doi:10.1038/jid.2010.412; published online 30 December 2010
INTRODUCTION
CD160 is a natural killer (NK) receptor initially identified as a
83-kDa molecule (Bensussan et al., 1994). CD160 appears to
be unique as it is encoded by a gene located on human
chromosome 1, it is expressed as a glycosylphosphatidylino-
sitol (GPI)-anchored molecule at the cell surface, and its
expression, which is induced upon lymphocyte activation, is
highly regulated by circulating CD4þCD25þ T regulatory
lymphocytes (Nikolova et al., 2009). CD160 was initially
shown to be expressed by CD56dim NK cells (Maiza et al.,
1993; Anumanthan et al., 1998; Agrawal et al., 1999), where
its engagement by major histocompatibility complex (MHC)
class I molecules triggers cytotoxicity and elicits cytokines
production (Le Bouteiller et al., 2002; Barakonyi et al., 2004).
CD160 was also shown to be expressed by CD8 T cells
(Nikolova et al., 2005; Rey et al., 2006), gd lymphocytes,
cutaneous dermal CD4þ T cells (Abecassis et al., 2007),
intestinal intraepithelial CD8þ T cells (Nikolova et al., 2005;
Rey et al., 2006), and, more recently, activated endothelial
cells (Fons et al., 2006). Recent data have shown that the
minor subset of circulating CD4þ T cells that express CD160
are activated lymphocytes. In these lymphocytes, crosslinking
of CD160 via an interaction with herpes virus entry mediator
(HVEM) inhibits the CD3- and CD28-mediated activation
(Cai et al., 2008). However, the function of CD160 in T cells
remains to be clarified, as it can act as a co-activating
receptor in CD28nul T lymphocytes (Nikolova et al., 2002).
Interestingly, CD160 was found to be expressed in mice, both
in NK cells (Maeda et al., 2005) and CD8þ -activated and
memory T cells (Tsujimura et al., 2006). In murine NK cells,
CD160 can interact with both classical and nonclassical
MHC class I molecules, as in humans, and CD1d (Maeda
et al., 2005). More recently, we have reported in NK cells a
transmembrane isoform of CD160, produced through alter-
native splicing of CD160 mRNA and obtained only upon
activation by IL-2, IL-12, or IL-15 (Giustiniani et al., 2009).
Finally, in human NK cells, we further identified a soluble
form of CD160, produced by phospholipase D (PLD)-specific
cleavage of the GPI anchor (Giustiniani et al., 2007), which
impairs ex vivo the cytotoxic CD8þ T-cell and NK cell
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functions, possibly by a competitive binding to MHC class I
molecules.
Mast cells (MCs) are key players of innate and adaptative
immunity and are involved in many allergic and inflamma-
tory diseases, especially in the skin. In the past 10 years, MCs
have been described for their regulatory functions of the
adaptative immunity (Secor et al., 2000; Lee et al., 2002;
Bryce et al., 2004; Grimbaldeston et al., 2006; Lu et al.,
2006), although the mechanisms by which they exert such
immunoregulatory effects remain unknown. To date, MCs
were not shown to produce regulatory mediators that may
directly interact with effector cytotoxic lymphocytes. In this
study, we show that human and mouse MCs produce soluble
CD160, a known ligand for classical and nonclassical MHC
class I molecules, previously shown to inhibit CD8þ
cytotoxic T lymphocyte activities.
RESULTS
CD160þ MCs are detected in human and murine tissues
Immunohistochemical studies revealed the presence of
CD160þ MCs in normal human skin (resident MCs),
inflammatory dermatoses (lichen, psoriasis (Figure 1a and b),
Figure 1. In situ immunostaining of human and murine tissues allows detection of CD160þ mast cells (MCs). (a, b) Single immunostaining of human
inflammatory skin from a patient with psoriasis showing MCs displaying cytoplasmic CD160 expression (a and left panel of b, arrowheads). MCs were
recognized morphologically and according to mast-cell tryptase expression (right panels of b, arrowheads). (c) In this skin sample from inflammatory skin
(contact hypersensitivity reaction), CD117/c-Kit (left panel) and CD160 (middle panel) expression both delineated MCs (arrowheads), whereas melanocytes,
used as internal controls, only express CD117, as expected (left panel, arrow), highlighting their dendritic morphology within basal keratinocytes. With double
stainings (right panel), the dermal MCs coexpressed CD117/c-Kit (red) and CD160 (brown) (arrowheads), whereas melanocytes remained only positive for
CD117/c-Kit (arrow). (d) Dermal resident MCs displayed a cytoplasmic granular expression of CD160 in skin biopsy samples from a nude mouse (arrowheads).
(e) A similar staining was seen in resident MCs of the intestine mucosa. Slides are shown at 100 original magnification in a, d, and e and 400 for b and c.
Bar¼0.05mm.
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eczema, mycosis fungoides, mastocytosis), and skin tumors
stroma (basal cell and squamous cell carcinomas, nevus,
melanoma, and neurofibroma). CD160þ resident MCs were
also identified in other organs (lung, colonic mucosae, and
salivary gland). CD160 was mostly expressed in the form
of a cytoplasmic granular staining. MCs were recognized
morphologically and using consecutive sections stained with
MC tryptase. Double-staining experiments revealed that
CD160þ cells in all cases were MCs, as they coexpressed
CD117 as shown in Figure 1c. In the nude mouse, CD160þ
tissue-resident MCs were identified in all investigated organs,
including the skin (Figure 1d) and intestine mucosae
(Figure 1e). We next analyzed the dorsal skin of wild-type
and MC-deficient KitW-sh/W-sh mice. As expected, we
identified CD160þ MCs in the dermis of the wild-type
mouse skin (Figure 2a), whereas a negative staining was
obtained in the deficient mouse (Figure 2b). Interestingly, in
mice reconstituted by intradermal injection of syngeneic fetal
skin MCs, CD160þ cells were readily detected in the deep
dermis, near to subcutaneous muscle (Figure 2c).
Two distinct transcripts corresponding to the two isoforms of
the GPI-anchored CD160 are expressed in the HMC-1 cell line
CD160 transcripts were detected in HMC-1 (human mast
cell line) cells. Interestingly, as in NK cells, two distinct
isoforms were evidenced, which are expected to correspond
to the GPI-anchored form of CD160 (CD160-GPI) and to
the CD160DIg-GPI variant (Figure 3a). The latter lacks the
sequences encoding for the extracellular immunoglobulin
domain. In contrast, the transcripts of the transmembrane
isoform of CD160 were not detected. The direct sequencing
of reverse transcriptase-PCR products clearly established that
they corresponded to wild CD160 mRNA, according to the
already described sequence in NK cells (Giustiniani et al.,
2009).
The HMC-1 cell line and cultured murine MCs display
intracellular expression of CD160 protein
Immunoprecipitation and immunoblotting of HMC-1 cell
lysates revealed a weak 83-kDa band that we interpreted as
the known trimeric form of CD160 (Figure 3b). In addition, at
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Figure 2. CD160þ cells are detected in C57BL/6-KitW-sh/W-sh mice only after reconstitution with syngeneic cultured mast cells (MCs). (a) CD160þ MCs
were detected in the dermis of the wild-type C57BL/6 mouse (left panel), otherwise characterized by toluidine blue staining (right panel), whereas no staining
was evidenced with the isotypic-matched antibody directed to CD106 (middle panel). (b) In the C57BL/6-KitW-sh/W-sh MC-deficient mouse, immunostaining
with anti-CD160 antibody was negative, as well as negative (CD106) and positive (toluidine blue) controls. (c) In the dorsal skin taken after reconstitution by
intradermal injection of syngeneic fetal skin-derived cultured MCs (þ ), CD160þ cells were seen in the dermis, with a similar staining with toluidine blue
(right panel). Slides are shown at  400 original magnification in a and  200 for b and c. Bar¼0.1mm.
918 Journal of Investigative Dermatology (2011), Volume 131
N Ortonne et al.
Mast Cells Produce Soluble CD160
longer exposure times, a shorter, barely detectable, 50-kDa
band was also seen (data not shown). Although it was difficult
to distinguish from the mAb light chains, this short band was
interpreted as a possible dimeric form of CD160. In addition,
CD160 staining of HMC-1 demonstrated an intracytoplasmic
granular staining pattern, consistent with expression of
CD160 in MC granules (Figure 3c). Similar results were
obtained with mouse MCs, including fetal skin MCs (FSMCs),
bone marrow MCs (BMMCs), and peritoneal MCs (PMCs)
(data not shown). Using flow cytometry on permeabilized
cells without supplemental pretreatment, the 2C7 mAb
detected CD160 only in BMMCs (Figure 4, left panels).
Interestingly, when the same experiment was conducted after
incubation of cells with monensine, before labeling, CD160
was observed in the three types of murine MCs analyzed
(Figure 4, right panels). When performed on unpermeabilized
HMC-1 cells, flow cytometry with anti-CD160 mAb showed
negative results.
The soluble form of CD160 (sCD160) is found in HMC-1 and
murine MC supernatants, and HMC-1 expresses the transcripts
for the GPI-PLD1 variant 2
After immunoprecipitation and immunoblotting of super-
natants of HMC-1 cells with anti-CD160 mAb (CL1-R2), we
observed, in addition to the expected 83 kDa band, a 50 kDa
molecule that might correspond to a dimeric form of CD160
(Figure 5a, right panel), whereas in mouse (FSMCs), only the
83 kDa band could be detected (Figure 5a, left panel).
Interestingly, HMC-1 cells, like the YT NK cell line used as
positive control, were found to express the GPI-PLD1 variant
2 transcript (Figure 5b), whereas, similar to NK cells, GPI-
PLD1 variant 1 was not detected.
Diminished expression of CD160 by dermal MCs in
inflammatory skin
In normal skin, all CD117 MCs expressed CD160. In skin
biopsies from inflammatory dermatoses, double-staining
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Figure 3. Detection of CD160 mRNA and protein in HMC-1 cell line. (a) Total mRNAs of HMC-1 were isolated and submitted to reverse transcription.
Amplification of both the membrane-bound (glycosylphosphatidylinositol (GPI)) and the transmembrane (TM) isoforms of CD160 together with b-actin
complementary DNA (cDNA) was performed using specific primers. The amplified products were separated on a 1% agarose gel. The CD160 Cos and Jurkat
cell lines were used as negative controls and the CD160þ NK92 cell line together with normal peripheral blood lymphocytes (PBLs) and natural killer (NK) cells
from a healthy donor were used as positive controls. (b) Immunoprecipitations of HMC-1 cell lysates were performed with anti-CD160 mAb (CL1-R2) or with
isotype-matched negative control antibody. The proteins were then transferred onto a nitrocellulose membrane and subjected to western blot analysis under
nonreductive conditions using the anti-CD160 (CL1-R2, 5mgml–1) and horseradish peroxidase (HRP)-conjugated goat anti-mouse antibodies. (c) Cytospin
slides of HMC-1 were immunostained with anti-CD160 (BY55, upper right panel), anti-CD117 (lower left panel), and anti-tryptase (lower, right panel) mAbs
followed by biotinylated secondary anti-mouse antibodies and avidin-biotin peroxidase complex using the Nexes device (Ventana). Slides were developed
with 30-30-diaminobenzidine and counterstained with hematoxylin. Bar¼ 0.02mm.
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experiments revealed that a proportion of CD117þ MCs
showed a low or almost negative staining for CD160. We
found a statistically significant reduction of CD160 expres-
sion by MCs in inflammatory areas in comparison with
resident MCs found in the neighboring, spared, areas as
illustrated in Figure 6a. Indeed, by direct counting at high-
power fields, we found a mean of 28% (range 6–48%) of MCs
with a strong CD160 expression (CD160þCD117þ ) in
inflammatory areas versus 83% (range 75–96%) in nonin-
flammatory areas (Figure 6b, Po0.0001). Altogether, these
findings support the hypothesis that dermal MCs release
CD160 during inflammatory processes in vivo.
In vitro inhibition of T-cell cytotoxicity by HMC-1 supernatant
is reversed by anti-CD160 mAb
As shown in Figure 6c, MHC-I-restricted CD8þ T-cell
cytotoxicity was partially reduced by incubation of the target
cells with HMC-1 supernatant, with an inhibition of 25% of
specific lysis, at both 15:1 and 7:1 effector-to-target ratios.
Interestingly, the inhibition was partially reversed when
anti-CD160 mAbs were added to medium.
DISCUSSION
MCs can regulate T-cell-mediated immune responses via
several mechanisms, including (1) MHC class I, II, and
costimulatory molecule-dependent antigen presentation
(Malaviya et al., 1996; Frandji et al., 1998), (2) elicitation
of T-cell migration to inflammatory sites (Rumsaeng et al.,
1997), (3) Th2 polarization of helper T cells (Jutel et al.,
2001), and (4) secretion of exosomes (Skokos et al., 2001,
2003; Valadi et al., 2007). On the other hand, MC functions
are in return regulated by T cells, as the regulatory
CD4þCD25þFoxP3þ T-cell subsets can suppress MC
degranulation through OX40–OX40L interaction (Gri et al.,
2008). Besides their proinflammatory role, MCs can also exert
antiinflammatory or immunosuppressive roles (Brain and
Williams, 1988; Hart et al., 1998), which may be increased
by UVB exposure in the skin (Byrne et al., 2008), including the
promotion of tissue allograft tolerance (Lu et al., 2006).
MCs were previously shown to express various surface
activating and inhibitory immune receptors, some of them
being known as NK receptors (Li and Yao, 2004). Besides
FcgRIIB, they express various inhibitory receptors bearing
ITIMs (immunoreceptor tyrosine-based inhibition motifs),
including Siglecs (sialic acid binding Ig-like lectins; Yokoi
et al., 2006; Bochner, 2009), the MC function-associated
antigen (Butcher et al., 1998), and LILRB4 (leukocyte
immunoglobulin-like receptor subfamily B member 4; Katz,
2007). Activating receptors consist of 2B4 (CD244; Romero
et al., 2004; Bachelet et al., 2006) and CD200R3 (Kojima
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Figure 4. Detection of CD160 protein in murine mast cells (MCs). Fetal skin
MCs (FSMCs), bone marrow MCs (BMMCs), and peritoneal mouse MCs
(PMCs) were fixed, permeabilized, and incubated with biotinylated anti-
CD160 mAb (2C7) for flow cytometry studies. Streptavidin-peroxidase
was used as negative control. Cells were permeabilized and analyzed with
(right panels) or without (left panel) previous incubation with monensine.
All experiments were done in duplicate.
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Figure 5. Presence of the soluble form of CD160 in culture cell supernatants
of human and murine mast cells (MCs) and detection of the transcript of
glycosylphosphatidylinositol-phospholipase D1 (GPI-PLD1) variant 2
protease in human MCs. (a) Immunoprecipitation of HMC-1 cells (right
figure) and fetal skin MC (FSMC; left figure) supernatants were performed with
anti-CD160 mAb (CL1-R2) or with isotype-matched control antibody. The
proteins were then transferred onto a nitrocellulose membrane and subjected
to western blot analysis using the anti-CD160 (CL1-R2, 5 mgml–1) and
horseradish peroxidase (HRP)-conjugated goat anti-mouse antibodies. The
migration was done under reductive condition for FSMCs and nonreductive
condition for HMC-1. Thus, the 55kDa band observed in the FSMC supernatant
is expected to correspond to mAb light chains. (b) Total mRNAs of HMC-1 cells
were isolated and submitted to reverse transcription. Amplifications of
complementary DNA (cDNA) of GPI-PLD variants 1 and 2 were performed
with specific primers. The amplified products were separated on a 1% agarose
gel. The natural killer (NK) cell line YT was used as a positive control.
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et al., 2007), in addition to the high-affinity receptor for IgE,
FceRI. Among these receptors, some are involved in the
regulation of the IgE-dependent activation of MCs (Yokoi
et al., 2008), whereas other are not, such as CD200R3
(Kojima et al., 2007).
Regarding MC/T-cell interactions, direct interactions
between MCs and MHC class I-restricted cytotoxic CD8þ T
cells are now well documented (Stelekati et al., 2009). The
finding of sCD160 in MC supernatants suggests that similar to
NK cells, sCD160 may prevent or impair the MHC class
I-restricted cytotoxic functions in vivo (Giustiniani et al.,
2007). The inhibitory effect of HMC-1 supernatant on MHC-I-
restricted cytotoxicity of CD8þ T cells, partially reversed by
anti-CD160 mAb that we evidenced in vitro, supports this
hypothesis. Interestingly, Cai et al. (2008) have shown that
CD160 can be expressed by activated CD4þ helper T cells,
where it may have inhibitory functions by interacting with
HVEM. In this study, we show that human and mouse MCs
produce and secrete sCD160. It is therefore conceivable that
MCs may also regulate helper T-cell function, by preventing
the interaction of membrane-bound CD160 with antigen-
presenting cell HVEM. Although structural traits regarding
soluble CD160 are lacking, sCD160 might be expressed in
HMC-1 as both 50 kDa dimeric and 83 kDa trimeric forms.
Of course, we cannot exclude that the 50 kD band observed
in immunoprecipitation experiments with the CL1-R2 mAb
rather represents a partially reduced form of the trimeric
CD160. It is noticeable that Cai et al. (2008) identified HVEM
as a ligand for CD160 using a construct in which the
extracellular domain of CD160 was fused to human IgG4 Fc
(CD160-Ig). Such construct can be expected to represent a
dimeric analog rather than the trimeric form of CD160. We
therefore wonder if the putative dimeric form of sCD160 may
act as a positive regulator of helper T-cell activation, by a
specific binding to HVEM expressed at the cell surface of
antigen-presenting cells, which may lead to conformational
changes or constitute a steric hindrance. The dominant
soluble form of CD160 produced by MCs may also be
regarded as a possible mechanism by which these cells could
contribute to control herpes virus infections, by preventing
virus entry into surface HVEM-expressing cells.
In NK cells, previous studies have shown that the release of
sCD160 relies on the proteolytic cleavage of the GPI motif by
PLD1. In these cells, the release of membrane-bound CD160
correlated with the de novo synthesis of PLD1 variant 2, upon
IL-15 treatment (Giustiniani et al., 2007). We show that both
humans (HMC-1) and murine MCs can express sCD160,
without the need of a cytokine pretreatment, and that CD160
seems to be released by MCs in the inflammatory areas of
pathologic skin. The mechanisms of CD160 release by MCs
remain to be further studied, but the assumption can be made
that CD160 may be associated within secretory granules, and
might be released during the degranulation process. In support
of this hypothesis, it is already known that human MCs express
PLDs, including those involved in the specific cleavage of GPI
structures (Metz et al., 1992). We also found that untreated
HMC-1 cells produce the PLD1 variant 2, shown to be involved
in the release of sCD160 in NK cells (Giustiniani et al., 2007).
Interestingly, PLD was actually shown to have an important role
in the degranulation process (Choi et al., 2002).
In conclusion, we have shown that human and murine
MCs constitutively express the GPI anchored isoform of
CD160. These cells are able to secrete CD160 in a soluble
form (sCD160), but unlike NK cells, without the need of IL-15
exposure. In addition, our results suggest that in MCs, CD160
might be produced as both dimeric and trimeric forms. The
function of CD160 produced by MCs in vivo remains to be
studied, especially to determine whether it might impair
CD8þ T-cell cytotoxicity, as observed in vitro, and/or may be
involved in the CD4þ helper T-cell activation, by preventing
HVEM-mediated inhibitory signals.
MATERIALS AND METHODS
Cells
The human MC line HMC-1, and Cos, Jurkat, YT, and NK-92 cell
lines were cultured at 37 1C in RPMI-1640 medium (Gibco,
Invitrogen, Brebie`res, France), supplemented with penicillin
(100 IUml–1), streptomycin (100mgml–1), L-glutamine (2mM), sodium
pyruvate (1%), and 10% of 56 1C-decomplemented fetal calf serum
(Hyclone, Perbio Sciences, Brebie`res, France). The medium was
supplemented with IL-3 and stem cell factor for the cultures of
murine FSMCs, BMMCs, and murine PMCs.
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Figure 6. Diminished expression of CD160 by mast cells (MCs) in
inflammatory skin areas and in vitro inhibition of major histocompatibility
complex (MHC)-I cytotoxicity by HMC-1 supernatant. (a) Human MCs
doubly stained with anti-CD160 (CL1-R2, red) and CD117 (brown), showing
a diminished expression of CD160 in inflammatory areas (arrowheads). MCs
with a strong CD160 expression (arrows) are more numerous within
noninflammatory areas (inset). Slides are shown at 400 original
magnification. Bar¼0.05mm. (b) Double-staining experiments were done in
nine skin biopsies. In each skin sample, the proportion of CD117 dermal MCs
showing a strong coexpression of CD160 (CD160þ /CD117þ cells) on doubly
stained slides was evaluated on 10 high-power fields (400 magnification)
from one area showing cellular inflammation and from another with no
inflammation. (c) 51Cr-release assay performed with irradiated Epstein–Barr
virus (EBV)-transformed B cells as target cells, labeled with Na51CrO4, plated
in 96-well V-bottom plates. The target cells were preincubated with medium
from HMC-1 cells alone or completed with IgG1 control or CL1-R2
antibodies. The effector cells were then added at various effector-to-target
(E:T) cell ratios, in triplicate. After 4 hours of culture, the determination of
51Cr release was done using a g-counter and the percentage of specific lysis
was determined (±SD). All experiments were done in triplicate.
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Peripheral blood mononuclear cells and NK cells were isolated
from the peripheral blood of healthy donors. Briefly, peripheral
blood mononuclear cells were isolated from heparinized venous
blood by density gradient centrifugation over lymphoprep (PAA
Laboratories, Linz, Austria). NK cells were purified using the MACS
NK cell isolation kit (Miltenyi Biotec, Paris, France). The selection of
in vitro allogeneic MHC-I-restricted effector T lymphocytes directed
toward Epstein–Barr virus-transformed B cells was performed as
previously reported (Giustiniani et al., 2007).
Antibodies
The anti-CD160 mAbs were the following: CL1-R2 (mouse IgG1)
and BY55 (mouse IgM), produced by us and which recognize both
human and murine forms of CD160, and 2C7, a biotinylated rat
IgG2a anti-mCD160 antibody kindly provided by Dr K Tsujimura
(Aichi Cancer Center Research Institute, Nagoya, Japan) (Tsujimura
et al., 2006). For immunohistochemical studies, we used a rabbit
anti-CD117/c-Kit antibody (Dako, Glostrup, Denmark) and the anti-
MC tryptase IgG1 mAb (AA1 clone, Abcam, Cambridge, MA).
Isotype-matched antibodies were used as negative controls: STA
(anti-CD106, IgG1), 5T-147 (IgM), and a biotinylated IGg2ak (BD
Biosciences, San Jose, CA).
Immunoprecipitation and immunoblotting
Immunoprecipitation and immunoblotting assays were done as
previously described (Giustiniani et al., 2007). Briefly, for super-
natants analyses, cells were washed in RPMI-1640 medium,
incubated for 4 hours, and supernatants were filtered and concen-
trated. For lysate analyses, cells were washed in phosphate-buffered
saline and resuspended in a lysis buffer. Lysates were centrifugated
for 15minutes at 4 1C and 13,000 r.p.m. to eliminate cellular debris
and nuclei. Immunoprecipitations were performed with CL1-R2
mAb or the negative control STA antibody. The proteins precipitated
with G-Sepharose beads were separated by SDS-6% PAGE in
nonreduced conditions for HMC-1 and reduced conditions for
FSMCs.
RNA extraction, reverse transcription-PCR, complementary
DNA amplification, and sequence analysis
Total RNA from 5 106 HMC-1 was isolated using the Trizol reagent
(Invitrogen, Cergy-Pontoise, France). Reverse transcription was
performed using an oligo-dT primer (Invitrogen) and the Prime
Script reverse transcriptase (Takara, Otsu, Japan). Specific primers
(Invitrogen) for the amplification of GPI-PLD1 variants 1 and 2 were
published sequences (Schofield and Rademacher, 2000). The
CD160 primers were either 50-ATGCTGTTGGAACCCGGCAGA
GGC-30 (forward) and 50-TTACAAAGCTTGAAGGGCCAC-30
(reverse) or 50-TGCAGGATGCTGTTGGAACCC-30 (forward) and
50-CCTGTGCCCTGTTGCATTCTTC-30 (reverse) flanking 219 and
546 or 339 and 665 base pair segments from the two alternatively
spliced short and long transcripts of the GPI-anchored CD160
isoforms. In addition, we searched for the transmembrane isoform of
CD160 using the following reverse primer: 50-TCAGTGA
AACTGGTTTGAACTTTCCTG -30, as previously described (Giustiniani
et al., 2009). b-Actin complementary DNA amplification was
performed in parallel as internal control. After initial denaturation
(94 1C, 2minutes), each complementary DNA sample was subjected
to denaturation (94 1C, 30 seconds), annealing (55 1C, 40 seconds),
and extension (72 1C, 60 seconds) steps for 35 cycles. The amplified
products were separated on a 1% agarose gel and sequenced with the
same CD160 oligonucleotide primers and two others (50-CAGCT
GAGACTTAAAAGGGATC-30 and 50-CACCAACACCATCTATCCGA
G-30), and analyzed with an automated fluorescent DNA sequencer
(ABI Prism/Applied Biosystems, Foster City, CA).
Animals
Female C57BL/6 and nude 6–8-week-old mice were purchased from
R Janvier (Laval, France). C57BL/6-KitW-sh/W-sh (KitW-sh/W-sh) MC-
deficient mice (Wolters et al., 2005) were used as a model to study
MC function in vivo. These mice were kindly provided from Peter
Besmer (Sloan-Kettering Institute, New York) and were bred in our
animal facility. All animal care and experimentation were conducted
in accord with the Pasteur Institute animal care and use committee
guidelines.
Preparation of murine MCs for MC-deficient mice
reconstitution
Mouse FSMCs are often used as a model of connective tissue-type
MCs that are distributed in the dermis. FSMCs were prepared
according to the method described by Yamada et al. (2003). After 4
weeks of culture in the presence of IL-3 and stem cell factor
(3 ngml–1), the cells express FceRI, can be sensitized with IgE, and
release histamine upon IgE aggregation, altogether showing a high
degree of maturity. For these reasons, a short-term 7-day reconstitu-
tion period was carried out. KitW-sh/W-sh mice (8 weeks old) were
reconstituted locally with MCs by intradermal injection in the dorsal
skin of 50 ml phosphate-buffered saline containing 2 106 FSMCs.
Mice were killed 7 days after MC reconstitution.
Tissue samples, immunohistochemistry, and analysis of the
density of CD160þ MCs
A total of 19 formalin-fixed, paraffin-embedded human tissue
samples were studied with normal (around a scar) and pathologic
human skin (lichen, psoriasis, eczema, mycosis fungoides, masto-
cytosis, basal cell and squamous cell carcinomas, nevus, melanoma,
and neurofibromas), and samples from human normal lung, colonic
mucosae, and salivary gland were retrieved from archival material.
Additionally, we analyzed formalin-fixed, paraffin-embedded tissue
samples from a nude mouse (skin, digestive tract, lung, heart, kidney,
spleen, and bone marrow) and dorsal skin sample from two wild
mice, two MC-deficient mice (KitW-sh/W-sh), and two MC-reconsti-
tuted (KitW-sh/W-sh) mice. HMC-1, murine FSMCs, BMMCs, and
PMCs were cytospinned using a Shandon cytospin 4 centrifuge
(Thermo Electron Corporation, Waltham, MA), air dried, and fixed
in aceton.
Immunohistochemical procedures were applied on 3mm thick
sections and cytospinned cells, either manually or using the Nexes
device (Ventana, Tucson, AZ). After antigen retrieval in heat with
citrate buffer, slides were incubated with the CL1-R2 mAb, followed
by a secondary biotinylated anti-mouse antibody and streptavidin-
alkaline phosphatase or streptavidin-peroxidase (Vectastain/Vector,
Burlingame, CA), developed with naphtol-fast red or diaminobenzi-
dine, respectively. For double-staining experiments, slides were then
incubated in H2O2 for 15minutes to block endogenous peroxidases
and 10minutes with blocking serum. Afterwards, slides were
incubated with the anti-CD117 rabbit antibodies, followed by a
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secondary anti-rabbit antibody conjugated with peroxidase for
35minutes (Impress) and finally developed in 30-30-diaminobenzidine
(Vectastain/Vector). All slides were counterstained with hematox-
ylin. Primary antibodies were used in a 1:50 dilution. Staining with
toluidine blue and MC tryptase expression were used as positive
controls for MCs.
For quantitative analyses of the CD160þ MC population in
human tissues, we performed direct counting of the CD160þ and
CD160 or CD160low MC subpopulations on sections doubly stained
with CD117 on 10 high-power fields ( 400 magnification). We
analyzed separately the inflammatory and noninflammatory areas
within each skin sample. Statistical analysis was done using Student’s
t-test with the Statview software (Abacus concept, Piscataway, NJ).
Flow cytometry
Murine FSMCs, BMMCs, and PMCs were fixed and permeabilized
(kit BD cytofix cytoperm with Golgi stop; BD Biosciences). Briefly,
the cells were incubated overnight at 4 1C in the ‘‘fixation-
permeabilization’’ solution from the kit. After washes, cells were
incubated with the specific mAb for 30minutes at 4 1C (CL1-R2,
BY55 and respective isotype-matched negative control antibodies).
Streptavidin-peroxidase (BD Pharmingen, San Jose, CA; streptavidin-
phycoerythrin) was used as negative control for 2C7. After washes,
cells were incubated with the appropriate FITC- or phycoerythrin-
labeled secondary antibodies. After washing, cells were analyzed by
flow cytometry on a FACScalibur (BD Biosciences). For golgi stop
experiments, cells were incubated before permeabilization with
monensine for 4 hours at 37 1C.
Lymphocyte-mediated cytotoxicity
Target cells were labeled with 100mCi of Na51CrO4 for 90minutes at
37 1C, washed in RPMI-1640 medium containing 10% fetal calf
serum, and plated in 96-well V-bottom microtiter plates (Greiner,
Courtaboeuf, France) for 1hour at 37 1C. When necessary, the target
cells were subjected to a preincubation step with 50ml of complete
medium or culture medium from HMC-1 cells completed with IgG1
control or CL1-R2 antibodies at 10mgml–1, 30minutes, at room
temperature. The effector cells were added on 103 target cells in 15:1
and 7:1 effector-to-target cell ratios. After 4hours of culture at 37 1C,
the plates were spun down and supernatants were collected for the
determination of 51Cr release with a gamma-counter (Packard
Instrument, Rungis, France). The percentage of specific lysis was
determined as previously reported (Giustiniani et al., 2007).
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